Loading the security page…
The series is stated in the current share scale after splits; dividends are not included in the price
United Therapeutics treats rare pulmonary hypertension and grows pig organs for transplantation into humans.
The core business is drugs for high blood pressure in the pulmonary artery, a rare and severe condition. The company offers several forms of one class of compound: tablets, inhalation, continuous subcutaneous infusion — the choice depends on the stage. That is steady revenue over a treatment course lasting years.
The second part sounds like science fiction and is nonetheless real: raising pigs with edited genomes whose kidneys and hearts are not rejected by the human body. The first transplants have already been performed. If the line succeeds it changes the company's scale radically; if not, years of investment are written off. The company pays no dividend.
Based on the last 12 months of reports, through 30 June 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
United Therapeutics Corporation (UTHR) is a company in the Health care sector; its shares trade on Nasdaq.
The price of United Therapeutics Corporation (UTHR) on November 2, 2026 is 597.73 $, −0.17 % on the day. Over 52 weeks the stock traded between 409.07 $ and 609.35 $; the price now sits 94 % of the way up that range. Over the past year the price changed by +25.29 %. The P/E ratio is 19.66, which is below the sector median (24.61). Market capitalization is 25.78 billion $, rank 14 among 380 stocks of the same industry with a known capitalization.
United Therapeutics Corporation trades on Nasdaq under the ticker UTHR. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks UTHR has traded between 409.07 $ and 609.35 $. As of 2 November 2026 the price stood 66.13 % of the way from the 52-week low to the high.
Over one year UTHR shares rose 25.29 %; over six months they fell 6.72 %. Volatility over 90 days is 32.53 %. Dividends are not included: this is price change only, as of 2 November 2026.
UTHR trades at a price-to-earnings ratio of 19.7, below the sector median of 24.6. Price to sales is 8.2, above the sector median of 3.6. Price to book is 4.0, above the sector median of 2.5. Calculated from reports for the period ending 30 June 2026.
United Therapeutics Corporation reported revenue of 3.2B $ and net income of 1.3B $ over the last four quarters. Net margin is 41.56 %. Revenue changed by +2.49 % year over year. Earnings per share are 27.91 $. Market capitalisation is 25.8B $.
UTHR has a return on equity of 20.48 %, above the sector median of −40.58 %. Return on assets is 18.16 %, above the sector median of −30.08 %. Operating margin is 44.44 %, above the sector median of −20.96 %.